SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacia Corp. a future biotech powerhouse?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Kucera who wrote ()5/23/2000 1:49:00 PM
From: Jack Hartmann   of 35
 
Pharmacia Drug May Inhibit Growth Of
Colorectal Cancer

Dow Jones Newswires

NEW ORLEANS -- Pharmacia Corp. (PHA) said preliminary results from a
study of its novel angiogenesis signaling inhibitor, SU5416, show that it may
inhibit the growth and spread of colorectal cancer.

Preliminary results for SU5416 show that when the drug is given to patients
with untreated, advanced colorectal cancer, the drug may extend the time
patients remain free of tumor growth and spread.

Pharmacia said Tuesday in a press release that Phase I/II data presented at
the annual meeting of the American Society of Clinical Oncology also suggest
SU5416 is well tolerated for at least one year when combined with
5-fluorouracil/leucovorin (5-FU/LV).

The study evaluated 28 patients. Patients with untreated advanced colorectal
cancer received increasing doses of SU5416 intravenously twice each week,
with standard doses of 5-FU/LV therd in the study, 41% had either complete
or partial response with 50% or greater shrinkage of tumor size.

Safety data has shown no dose-limiting toxicity attributable to SU5416, with
three patients remaining on therapy for more than one year. Toxicities seen
are predominantly those known to occur with 5-FU/LV.

SU5416 works by inhibiting angiogenesis. Angiogenesis is the process by
which tumors create their own blood supply to provide nutrients and oxygen
essential for their growth.

Pharmacia is also conducting a pilot study of SU5416 in combination with
Camptosar, Pharmacia's chemotherapeutic agent, and 5-FU/LV, for the
treatment of metastatic colorectal cancer. The pharmaceutical company is also
researching oral forms of SU5416.

-Elizabeth Souder; Dow Jones Newswires; 201-938-5400
************
Nothing but good news here on this company. Wish a little cheaper.
Jack
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News